Efficacy of revascularization in CTO patients based on hibernating myocardium therapy
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14237 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Wenjie Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Coronary Artery Disease (CCAD), Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical Unive…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Coronary Occlusion, Myocardial Stunning, Tomography, Emission-Computed, Single-Photon. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Beijing Hospitals Authority Youth Programme, Young Elite Scientists Sponsorship Program by BAST, Major State Basic Research Development Program of China.
Abstract (Originalsprache)
Background
The effectiveness of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) is still uncertain, especially for patients with ischemic left ventricular dysfunction. This study aimed to assess hibernating myocardium (HM), as determined by single‐photon emission computed tomography (SPECT) and 18 F‐FDG positron emission tomography (PET), and to compare the benefits of PCI and optimal medical therapy (OMT).
Methods
A retrospective study collected data from 332 patients with CTO and ischemic left ventricular dysfunction. The study compared patients who underwent PCI or OMT via propensity score matching (PSM) analysis which was performed with a 1:2 matching protocol using the nearest neighbour matching algorithm. The primary endpoint of the study was the occurrence of major adverse cardiac events (MACE), defined as a composite of cardiac death, readmission for worsening heart failure (WHF), revascularization and myocardial infarction (MI).
Results
After PSM, there were a total of 246 individuals in the PCI and OMT groups. Following Cox regression, hibernating myocardium/total perfusion defect (HM/TPD) was identified as an independent risk factor (hazard ratio (HR): 1.03, 95% confidence interval (CI): 1.008–1.052, p = .007). The cut‐off value of HM/TPD was 38%. The results of the subgroup analysis suggest that for patients with HM/TPD >38%, the OMT group had a greater risk of MACE ( p = .035). A sensitivity analysis restricting patients with single‐vessel CTO lesions, HM/TPD remained an independent predictor (HR 1.025, 95% CI 1.008–1.043, p = .005).
Conclusion
HM/TPD is an independent predictor of MACE, and for patients with HM/TPD > 38%, CTO‐PCI had a lower risk of MACE compared with OMT. However, further validation is still needed through large‐scale studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Coronary Artery Disease (CCAD), Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Beijing Institute of Heart Lung and Blood Vessel Disease, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Wenjie Chen, Yuchen Shi
Förderung
- Beijing Hospitals Authority Youth Programme
- Young Elite Scientists Sponsorship Program by BAST
- Major State Basic Research Development Program of China
- National Natural Science Fund of China
Zitieren
APA
Chen, W., Du, Z., Qin, Y., Zheng, Z., Liu, J., & Shi, Y. (2024). Efficacy of revascularization in CTO patients based on hibernating myocardium therapy. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14237
Vancouver
Chen W, Du Z, Qin Y, Zheng Z, Liu J, Shi Y. Efficacy of revascularization in CTO patients based on hibernating myocardium therapy. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14237
BibTeX
@article{Chen2024,
author = {Chen, Wenjie and Du, Zhiyong and Qin, Yanwen and Zheng, Ze and Liu, Jinghua and Shi, Yuchen},
title = {Efficacy of revascularization in CTO patients based on hibernating myocardium therapy},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14237}
}
EUVIMED